Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 897 of 5804
-
Can short bursts of intense exercise ease knee arthritis and protect the heart?
Symptom relief CompletedThe study aims to compare the effects of an education and High Intensity Interval Training program (eHIIT) with the widely used Neuromuscular Exercise and education program (NEMEX-e) on knee OA symptoms and risk factors for cardiovascular disease in people with knee OA and at lea…
Phase: NA • Sponsor: Frederiksberg University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail targets Hard-to-Treat stomach cancer
Disease control Recruiting nowThis study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Phase: PHASE1, PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Custom drug targets rare genetic brain disease in First-Ever human test
Disease control OngoingThis research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide expansion in ATN1
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New dengue drug could cut fever time and virus levels
Disease control Recruiting nowThe purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Every-8-Week shot could simplify PNH treatment
Disease control OngoingThe purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH.
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a simple ointment replace surgery for some skin cancers?
Disease control Recruiting nowhis is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not arising on the face or scalp
Phase: PHASE2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New heart failure pill shows promise in Mid-Stage trial
Disease control CompletedThe purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
Phase: PHASE2 • Sponsor: Cardurion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
RSV nasal vaccine trial for kids halted – what we know
⭐️ VACCINE ⭐️ TerminatedThis study is a phase III, randomized, observer-blind, placebo-controlled, multinational, multi-center study to be conducted in approximately 6300 children 6 months to \< 22 months of age. The purpose of the study is to evaluate the efficacy, immunogenicity, and safety of Respira…
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
New Weight-Loss drug shows promise in early trial
Disease control CompletedThe main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
AI could spot breast cancer risk better than current methods
Diagnosis Recruiting nowAccurate risk assessment is essential for the success of population screening programs and early detection efforts in breast cancer. Mirai is a new deep learning model based on full resolution mammograms. Mirai is a mammography-based deep learning model designed to predict risk …
Phase: NA • Sponsor: University of Massachusetts, Worcester • Aim: Diagnosis
Last updated Jun 27, 2026 08:08 UTC
-
Which oxygen device best prevents Re-Intubation in High-Risk ICU patients?
Disease control CompletedIn intensive care units (ICUs), approximately 10% to 15%of patients ready to be separated from a ventilator experience extubation failure leading to reintubation. In patients considered at high risk, these rates can even exceed 20%. Because reintubation is associated with particu…
Phase: NA • Sponsor: Assiut University • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Eye drops could replace needles for wet AMD? new trial underway
Disease control OngoingThe purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
Phase: PHASE2 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a common gout pill protect the heart and lungs during surgery?
Disease control Recruiting nowAll patients will be completed collection of demographic data, clinical data, and be observed for inflammatory organ damage, oxygenation index or SpO2/ FIO2, WBC, NEU, interleukin-1β, interleukin-6, interleukin-8 (IL-1β/6/8), tumor necrosis factor-α (TNF-α), C-reactive protein (C…
Phase: PHASE3 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New blood test could spot genetic diseases before birth
Diagnosis Recruiting nowThe purpose of this research is to develop and validate a single gene Non-Invasive Prenatal Test. The development of this investigational single-gene noninvasive prenatal testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), Sickle cell dise…
Sponsor: Natera, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New drug mosunetuzumab takes on rituximab in rare lymphoma trial
Disease control Recruiting nowThis phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a higher dose of rifampicin beat TB faster?
Disease control Recruiting nowThe goal of this clinical trial is to compare an optimized dose (1800 mg) of rifampicin to standard dose (450 mg if patient \<50 kg and 600 mg if patient \>50kg) of rifampicin in tuberculosis patients. The main questions it aims to answer are: * To compare the incidence of hepa…
Phase: PHASE3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Simple C-Section techniques could slash postpartum bleeding risk
Disease control CompletedPostpartum hemorrhage is the leading cause of maternal deaths in all over the world, especially in developing and underdeveloped countries. Medical and surgical methods exist for management of bleeding. There are two surgical techniques for removal of the placenta on cesarean de…
Sponsor: Busra Lekesiz • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could two common drugs boost sleep apnea surgery success?
Disease control Recruiting nowThis study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).
Phase: PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat cancer spread
Disease control CompletedThe goal of this prospective, single-arm exploratory clinical study is to explore the safty and efficacy of whole-brain radiotherapy combined with Thiotepa intrathecal injection combined with systemic therapy for the primary disease in the treatment of leptoeningeal metastases in…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New dosing strategy aims to reduce eye damage from myeloma drug
Disease control Recruiting nowThis phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond to treatment (or that has not responded to previou…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC